Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
5,401
archived clinical trials in
Alzheimer Disease

A Phase 2 Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer's Disease
A Double Blind, Placebo Controlled, Randomized, Multicenter Study Evaluating The Efficacy And Safety Of Eighteen Months Of Treatment With PF 04494700 (TTP488) In Participants With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Pfizer Investigational Site
mi
from
Providence, RI
A Phase 2 Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer's Disease
A Double Blind, Placebo Controlled, Randomized, Multicenter Study Evaluating The Efficacy And Safety Of Eighteen Months Of Treatment With PF 04494700 (TTP488) In Participants With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Pfizer Investigational Site
mi
from
Providence, RI
Click here to add this to my saved trials
A Phase 2 Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer's Disease
A Double Blind, Placebo Controlled, Randomized, Multicenter Study Evaluating The Efficacy And Safety Of Eighteen Months Of Treatment With PF 04494700 (TTP488) In Participants With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Pfizer Investigational Site
mi
from
Charleston, SC
A Phase 2 Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer's Disease
A Double Blind, Placebo Controlled, Randomized, Multicenter Study Evaluating The Efficacy And Safety Of Eighteen Months Of Treatment With PF 04494700 (TTP488) In Participants With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Pfizer Investigational Site
mi
from
Charleston, SC
Click here to add this to my saved trials
A Phase 2 Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer's Disease
A Double Blind, Placebo Controlled, Randomized, Multicenter Study Evaluating The Efficacy And Safety Of Eighteen Months Of Treatment With PF 04494700 (TTP488) In Participants With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Pfizer Investigational Site
mi
from
North Charleston, SC
A Phase 2 Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer's Disease
A Double Blind, Placebo Controlled, Randomized, Multicenter Study Evaluating The Efficacy And Safety Of Eighteen Months Of Treatment With PF 04494700 (TTP488) In Participants With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Pfizer Investigational Site
mi
from
North Charleston, SC
Click here to add this to my saved trials
A Phase 2 Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer's Disease
A Double Blind, Placebo Controlled, Randomized, Multicenter Study Evaluating The Efficacy And Safety Of Eighteen Months Of Treatment With PF 04494700 (TTP488) In Participants With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Pfizer Investigational Site
mi
from
Nashville, TN
A Phase 2 Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer's Disease
A Double Blind, Placebo Controlled, Randomized, Multicenter Study Evaluating The Efficacy And Safety Of Eighteen Months Of Treatment With PF 04494700 (TTP488) In Participants With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Pfizer Investigational Site
mi
from
Nashville, TN
Click here to add this to my saved trials
A Phase 2 Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer's Disease
A Double Blind, Placebo Controlled, Randomized, Multicenter Study Evaluating The Efficacy And Safety Of Eighteen Months Of Treatment With PF 04494700 (TTP488) In Participants With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Pfizer Investigational Site
mi
from
Dallas, TX
A Phase 2 Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer's Disease
A Double Blind, Placebo Controlled, Randomized, Multicenter Study Evaluating The Efficacy And Safety Of Eighteen Months Of Treatment With PF 04494700 (TTP488) In Participants With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Pfizer Investigational Site
mi
from
Dallas, TX
Click here to add this to my saved trials
A Phase 2 Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer's Disease
A Double Blind, Placebo Controlled, Randomized, Multicenter Study Evaluating The Efficacy And Safety Of Eighteen Months Of Treatment With PF 04494700 (TTP488) In Participants With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Pfizer Investigational Site
mi
from
Houston, TX
A Phase 2 Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer's Disease
A Double Blind, Placebo Controlled, Randomized, Multicenter Study Evaluating The Efficacy And Safety Of Eighteen Months Of Treatment With PF 04494700 (TTP488) In Participants With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Pfizer Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
A Phase 2 Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer's Disease
A Double Blind, Placebo Controlled, Randomized, Multicenter Study Evaluating The Efficacy And Safety Of Eighteen Months Of Treatment With PF 04494700 (TTP488) In Participants With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Pfizer Investigational Site
mi
from
Salt Lake City, UT
A Phase 2 Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer's Disease
A Double Blind, Placebo Controlled, Randomized, Multicenter Study Evaluating The Efficacy And Safety Of Eighteen Months Of Treatment With PF 04494700 (TTP488) In Participants With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Pfizer Investigational Site
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Phase 2 Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer's Disease
A Double Blind, Placebo Controlled, Randomized, Multicenter Study Evaluating The Efficacy And Safety Of Eighteen Months Of Treatment With PF 04494700 (TTP488) In Participants With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Pfizer Investigational Site
mi
from
Seattle, WA
A Phase 2 Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer's Disease
A Double Blind, Placebo Controlled, Randomized, Multicenter Study Evaluating The Efficacy And Safety Of Eighteen Months Of Treatment With PF 04494700 (TTP488) In Participants With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Pfizer Investigational Site
mi
from
Seattle, WA
Click here to add this to my saved trials
A Phase 2 Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer's Disease
A Double Blind, Placebo Controlled, Randomized, Multicenter Study Evaluating The Efficacy And Safety Of Eighteen Months Of Treatment With PF 04494700 (TTP488) In Participants With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Pfizer Investigational Site
mi
from
Madison, WI
A Phase 2 Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer's Disease
A Double Blind, Placebo Controlled, Randomized, Multicenter Study Evaluating The Efficacy And Safety Of Eighteen Months Of Treatment With PF 04494700 (TTP488) In Participants With Mild To Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Pfizer Investigational Site
mi
from
Madison, WI
Click here to add this to my saved trials
Efficacy of Circadin® 2 mg in Patients With Mild to Moderate Alzheimer Disease Treated With AChE Inhibitor
A Double-blind, Parallel Group, Randomized, Placebo Controlled Study of the Efficacy of Circadin® 2mg in Patients With Mild to Moderate Alzheimer Disease (AD) Treated With Acetylcholinesterase (AChE) Inhibitor
Status: Enrolling
Updated:  12/31/1969
Meridien Research
mi
from
Brooksville, FL
Efficacy of Circadin® 2 mg in Patients With Mild to Moderate Alzheimer Disease Treated With AChE Inhibitor
A Double-blind, Parallel Group, Randomized, Placebo Controlled Study of the Efficacy of Circadin® 2mg in Patients With Mild to Moderate Alzheimer Disease (AD) Treated With Acetylcholinesterase (AChE) Inhibitor
Status: Enrolling
Updated: 12/31/1969
Meridien Research
mi
from
Brooksville, FL
Click here to add this to my saved trials
Efficacy of Circadin® 2 mg in Patients With Mild to Moderate Alzheimer Disease Treated With AChE Inhibitor
A Double-blind, Parallel Group, Randomized, Placebo Controlled Study of the Efficacy of Circadin® 2mg in Patients With Mild to Moderate Alzheimer Disease (AD) Treated With Acetylcholinesterase (AChE) Inhibitor
Status: Enrolling
Updated:  12/31/1969
Meridien Research
mi
from
Saint Petersburg, FL
Efficacy of Circadin® 2 mg in Patients With Mild to Moderate Alzheimer Disease Treated With AChE Inhibitor
A Double-blind, Parallel Group, Randomized, Placebo Controlled Study of the Efficacy of Circadin® 2mg in Patients With Mild to Moderate Alzheimer Disease (AD) Treated With Acetylcholinesterase (AChE) Inhibitor
Status: Enrolling
Updated: 12/31/1969
Meridien Research
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
Efficacy of Circadin® 2 mg in Patients With Mild to Moderate Alzheimer Disease Treated With AChE Inhibitor
A Double-blind, Parallel Group, Randomized, Placebo Controlled Study of the Efficacy of Circadin® 2mg in Patients With Mild to Moderate Alzheimer Disease (AD) Treated With Acetylcholinesterase (AChE) Inhibitor
Status: Enrolling
Updated:  12/31/1969
Exodon LLC
mi
from
Mount Arlington, NJ
Efficacy of Circadin® 2 mg in Patients With Mild to Moderate Alzheimer Disease Treated With AChE Inhibitor
A Double-blind, Parallel Group, Randomized, Placebo Controlled Study of the Efficacy of Circadin® 2mg in Patients With Mild to Moderate Alzheimer Disease (AD) Treated With Acetylcholinesterase (AChE) Inhibitor
Status: Enrolling
Updated: 12/31/1969
Exodon LLC
mi
from
Mount Arlington, NJ
Click here to add this to my saved trials
Efficacy of Circadin® 2 mg in Patients With Mild to Moderate Alzheimer Disease Treated With AChE Inhibitor
A Double-blind, Parallel Group, Randomized, Placebo Controlled Study of the Efficacy of Circadin® 2mg in Patients With Mild to Moderate Alzheimer Disease (AD) Treated With Acetylcholinesterase (AChE) Inhibitor
Status: Enrolling
Updated:  12/31/1969
Scranton Medical Institute
mi
from
Scranton, PA
Efficacy of Circadin® 2 mg in Patients With Mild to Moderate Alzheimer Disease Treated With AChE Inhibitor
A Double-blind, Parallel Group, Randomized, Placebo Controlled Study of the Efficacy of Circadin® 2mg in Patients With Mild to Moderate Alzheimer Disease (AD) Treated With Acetylcholinesterase (AChE) Inhibitor
Status: Enrolling
Updated: 12/31/1969
Scranton Medical Institute
mi
from
Scranton, PA
Click here to add this to my saved trials
Efficacy of Circadin® 2 mg in Patients With Mild to Moderate Alzheimer Disease Treated With AChE Inhibitor
A Double-blind, Parallel Group, Randomized, Placebo Controlled Study of the Efficacy of Circadin® 2mg in Patients With Mild to Moderate Alzheimer Disease (AD) Treated With Acetylcholinesterase (AChE) Inhibitor
Status: Enrolling
Updated:  12/31/1969
Merchav clinics
mi
from
Tel-Aviv,
Efficacy of Circadin® 2 mg in Patients With Mild to Moderate Alzheimer Disease Treated With AChE Inhibitor
A Double-blind, Parallel Group, Randomized, Placebo Controlled Study of the Efficacy of Circadin® 2mg in Patients With Mild to Moderate Alzheimer Disease (AD) Treated With Acetylcholinesterase (AChE) Inhibitor
Status: Enrolling
Updated: 12/31/1969
Merchav clinics
mi
from
Tel-Aviv,
Click here to add this to my saved trials
Wii-fit for Activity, Balance and Gait in Assisted Living
Wii-fit for Activity, Balance and Gait in Assisted Living
Status: Enrolling
Updated:  12/31/1969
Parson's House Assisted Living
mi
from
Omaha, NE
Wii-fit for Activity, Balance and Gait in Assisted Living
Wii-fit for Activity, Balance and Gait in Assisted Living
Status: Enrolling
Updated: 12/31/1969
Parson's House Assisted Living
mi
from
Omaha, NE
Click here to add this to my saved trials
Apathy in Dementia Methylphenidate Trial (ADMET)
Apathy in Dementia Methylphenidate Trial (ADMET)
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins University
mi
from
Baltimore, MD
Apathy in Dementia Methylphenidate Trial (ADMET)
Apathy in Dementia Methylphenidate Trial (ADMET)
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Apathy in Dementia Methylphenidate Trial (ADMET)
Apathy in Dementia Methylphenidate Trial (ADMET)
Status: Enrolling
Updated:  12/31/1969
Medical University of South Carolina
mi
from
Charleston, SC
Apathy in Dementia Methylphenidate Trial (ADMET)
Apathy in Dementia Methylphenidate Trial (ADMET)
Status: Enrolling
Updated: 12/31/1969
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Apathy in Dementia Methylphenidate Trial (ADMET)
Apathy in Dementia Methylphenidate Trial (ADMET)
Status: Enrolling
Updated:  12/31/1969
Sunnybrook Health Sciences Centre
mi
from
Toronto,
Apathy in Dementia Methylphenidate Trial (ADMET)
Apathy in Dementia Methylphenidate Trial (ADMET)
Status: Enrolling
Updated: 12/31/1969
Sunnybrook Health Sciences Centre
mi
from
Toronto,
Click here to add this to my saved trials
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients With Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Miami, FL
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients With Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients With Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Indianapolis, IN
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients With Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients With Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Brooklyn, NY
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients With Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients With Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Norfolk, VA
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients With Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Norfolk, VA
Click here to add this to my saved trials
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients With Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Seattle, WA
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients With Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients With Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Phoenix, AZ
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients With Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients With Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Sun City, AZ
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients With Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Sun City, AZ
Click here to add this to my saved trials
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients With Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Little Rock, AR
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients With Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Little Rock, AR
Click here to add this to my saved trials
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients With Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Carson, CA
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients With Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Carson, CA
Click here to add this to my saved trials
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients With Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Laguna Hills, CA
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients With Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Laguna Hills, CA
Click here to add this to my saved trials
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients With Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Lomita, CA
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients With Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Lomita, CA
Click here to add this to my saved trials
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients With Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Los Angeles, CA
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients With Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients With Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Oxnard, CA
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients With Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Oxnard, CA
Click here to add this to my saved trials
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients With Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
San Diego, CA
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients With Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients With Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
San Francisco, CA
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients With Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
San Francisco, CA
Click here to add this to my saved trials
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients With Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Santa Ana, CA
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients With Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Santa Ana, CA
Click here to add this to my saved trials
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients With Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Santa Monica, CA
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients With Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Santa Monica, CA
Click here to add this to my saved trials
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients With Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Denver, CO
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients With Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Denver, CO
Click here to add this to my saved trials
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients With Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Fairfield, CT
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients With Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Fairfield, CT
Click here to add this to my saved trials
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients With Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Hamden, CT
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients With Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Hamden, CT
Click here to add this to my saved trials
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients With Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
New Haven, CT
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients With Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
New Haven, CT
Click here to add this to my saved trials
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients With Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Norwalk, CT
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients With Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Norwalk, CT
Click here to add this to my saved trials
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients With Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Newark, DE
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients With Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Newark, DE
Click here to add this to my saved trials
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients With Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Washington,
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients With Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Washington,
Click here to add this to my saved trials
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients With Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Boca Raton, FL
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients With Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Boca Raton, FL
Click here to add this to my saved trials
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients With Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Fort Myers, FL
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients With Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients With Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Hollywood, FL
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients With Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Hollywood, FL
Click here to add this to my saved trials
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients With Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Miami Springs, FL
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients With Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Miami Springs, FL
Click here to add this to my saved trials
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients With Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Orange City, FL
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients With Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Orange City, FL
Click here to add this to my saved trials
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients With Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Orlando, FL
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients With Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients With Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Sunrise, FL
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients With Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Sunrise, FL
Click here to add this to my saved trials
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients With Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Tampa, FL
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients With Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials